Korean Market
EXCH
Onconic Therapeutics
★

Phase 1 Clinical Trial Amendment Approved for Nasogastric Administration of Jakubo ODT, Potential Label Expansion Enhances Product Value

 
EXCH
Onconic Therapeutics
★

Onconic Therapeutics Files Phase 3 IND for H. pylori Eradication Indication of Jakubozin (JP-1366) – Expansion of Approved Drug's Label, Limited Short-Term Impact but Positive Long-Term Value

 
EXCH
Onconic Therapeutics
★★

Phase 1 IND Amendment for Nasogastric Tube Administration of JLP-2302

 
PERI
Onconic Therapeutics
★★★

Onconic Therapeutics 2026 Q1 Strong Performance: Revenue Surge and Sustained Profitability

 
OWNR
Onconic Therapeutics
★

Empty Report on Ownership of Specific Securities by Executives/Major Shareholders